ArticleFrontiers in pharmacology2025
Case Report: Neurofilament light chain in the follow up of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with ocrelizumab.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive multifocal leukoencephalopathy (PML) results from the reactivation of John Cunningham virus JC virus and is a rare complication of anti-CD20 drug therapy. Neurofilament light chains increasingly serve as a marker of neuroaxonal damage in the follow-up of patients with multiple sclerosis (MS), but its role in the monitoring and detection of processes such as PML is yet to be defined. We report the case of a patient with MS who was treated with ocrelizumab and developed PML. Results: Serum neurofilament light chain (sNFL) levels were elevated at the diagnosis and progressively increased over his follow-up. Our results suggest that the monitoring of sNFL levels may be useful for the early diagnosis of PML in patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.